BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report report published on Tuesday,MarketScreener reports.

Other equities research analysts have also recently issued research reports about the company. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. BMO Capital Markets decreased their target price on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research note on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $140.00 target price on shares of BioNTech in a research report on Thursday, December 11th. Finally, Citigroup lowered their price target on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Thirteen analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Stock Performance

Shares of BNTX stock opened at $94.86 on Tuesday. BioNTech has a one year low of $79.52 and a one year high of $124.00. The firm’s 50 day moving average price is $106.24 and its 200-day moving average price is $102.43. The firm has a market cap of $22.76 billion, a P/E ratio of -18.10 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Larson Financial Group LLC raised its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares in the last quarter. EFG International AG acquired a new position in BioNTech during the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares during the period. Financial Consulate Inc. bought a new position in shares of BioNTech in the 3rd quarter valued at about $36,000. Finally, Huntington National Bank boosted its stake in BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.